Founded in 1987, MedImmune is a pharmaceutical health care company that develops medications for the treatment of cancer, inflammatory diseases and pediatric infections. The company markets products under the trade names of Synagis, Ethyol, FluMist and CytoGam. With more than 3,000 employees, it has operations in the United States, the United Kingdom and the Netherlands. MedImmune offers a selection of clinical testing products for the detection of cardiovascular and gastrointestinal diseases. The company provides the HUMIRA brand of medicine for the treatment of crohns disease, ankylosing spondylitis rheumatoid, chronic plaque psoriasis and juvenile rheumatoid arthritis. In addition, it assists with the development of investigational human monoclonal antibodies for targeting interferon alpha in patients with systemic lupus erythematosus.